Forest Whistleblower Cases Settle for Over $300 Million
Nolan & Auerbach, P.A. announces another successful whistleblower recovery by their courageous clients, whose cases continue to return hundreds of millions of dollars to the…
Read More »Pharma 101 – Pharmaceutical Fraud
Pharmaceutical Fraud News & Insight form the Qui Tam and False Claims Act Perspective
Contact FormTag Archives: Pharmaceutical Fraud
Botox Whistleblower Case Settles for $600 Million
Pharmaceutical manufacturer Allergan, Inc. has agreed to pay $225 million to resolve civil allegations that it unlawfully promoted its drug Botox® Therapeutic for unapproved uses…
Read More »Out of the U.S. No Oversight Necessary?
Today the OIG posted "Challenges to FDA's Ability To Monitor and Inspect Foreign Clinical Trials" (OEI-01-08-00510). As all new investigational drugs and biologics must undergo…
Read More »Consequences of Pharmaceutical Fraud Settlements: Off-Label Marketing Continues?
Reporter Susan Todd wrote a fine article in the June 6, 2010 Star –Ledger about off-label marketing. “There are very few companies that haven’t had…
Read More »GI Drug Overhyped, Warns FDA
On May 5th, the FDA posted a letter sent to Shire Development, Inc. regarding the marketing of LIALDA, an oral sustained release multimatrix formulation of…
Read More »Johnson & Johnson Subsidiaries to Pay More Than $81 Million to Resolve Allegations of Off-Label Promotion of Topamax
American pharmaceutical manufacturers Ortho-McNeil Pharmaceutical LLC and Ortho-McNeil-Janssen Pharmaceuticals Inc., both subsidiaries of Johnson & Johnson, have agreed to pay more than $81 million to…
Read More »AstraZeneca Agrees to $520 Million Settlement
Attorney General Eric Holder announced April 27, 2010, that AstraZeneca has agreed to pay $520 million to federal and state taxpayers to settle claims that…
Read More »FDA Warns Pfizer About Pediatric Trials of Geodon
On April 9th, the FDA issued a Warning Letter to Pfizer, Inc. concerning its conduct during a clinical trial for one of its prescription drugs…
Read More »Alpharma to Pay $42.5 Million to Resolve False Claims Act Allegations
Pharmaceutical manufacturer Alpharma, Inc. has agreed to pay $42.5 million to resolve False Claims Act allegations in connection with the marketing of the morphine-based drug,…
Read More »Guidant Charged in Failure to Report Defibrillator Safety Problems to FDA
Medical device manufacturer Guidant LLC, a wholly-owned subsidiary of Boston Scientific Corporation, was charged Feb. 25, 2010 with criminal violations of the Federal Food, Drug,…
Read More »